Rigel Pharmaceuticals has granted AstraZeneca an exclusive worldwide license for development and commercialization of its R256 inhaled JAK inhibitor for the treatment for moderate to severe asthma. The deal includes an upfront payment of $1 million with a potential $8.25 million in milestone payments by the end of next year; according to the two companies, the total … [Read more...] about Rigel licenses inhaled JAK inhibitor to AstraZeneca
Business
Analyst predicts slight increase in asthma and COPD drug market over next five years
A new report from Transparency Market Research titled "Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017" predicts an increase in the asthma and COPD drug market from ~25 billion in 2010 to ~27 billion in 2017. The report suggests that price erosion and the expiration of patents with few novel drugs … [Read more...] about Analyst predicts slight increase in asthma and COPD drug market over next five years
Impel NeuroPharma announces advances in development of pressurized olfactory device
Impel NeuroPharma says that a study has shown that its Pressurized Olfactory Device (POD) was preferred 2 to 1 by testers compared to conventional nasal sprays. POD delivers aerosolized drug, both liquid and powder formulations, to the upper nasal cavity, allowing delivery of therapeutics across the blood-brain barrier, according to Impel. The company says that it … [Read more...] about Impel NeuroPharma announces advances in development of pressurized olfactory device
Bespak MDI valve sales up 12%
Consort Medical has announced record revenue and profits for the year ending April 30, 2012, including a 12% increase in revenue for its Bespak division, which manufactures metered dose inhaler valves and actuators as well as dry powder inhalers. Bespak's operating profit also grew by 17%. According to Consort, the growth in Bespak revenue came about in part due to … [Read more...] about Bespak MDI valve sales up 12%
Savara announces Phase I study results for AeroVanc, funding for Phase 2
Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis. According to the company, the study demonstrated that AeroVanc was well tolerated, that clearance of the … [Read more...] about Savara announces Phase I study results for AeroVanc, funding for Phase 2
Pharmaxis submits NDA for Bronchitol, issues update on commercialization in Europe
Pharmaxis has submitted an NDA for Bronchitol inhaled dry powder mannitol for the treatment of cystic fibrosis to the FDA. Pharmaxis CEO Dr Alan Robertson said, “The submission marks the second of two key milestones for the Bronchitol program following approval last month to market the product in Europe. Cystic fibrosis patients have a life‐limiting disease. It … [Read more...] about Pharmaxis submits NDA for Bronchitol, issues update on commercialization in Europe
Insmed to defer Phase 3 study of Arikace in US
According to Insmed, the company has decided to focus on European and Canadian studies of its Arikace liposomal amikacin for inhalation and to put a US Phase 3 study on the back burner. The CLEAR-108 (CLinical Evaluation of ARikace) Phase 3 study of Arikace for the treatment of patients with cystic fibrosis is already underway in Europe and Canada, and Insmed says … [Read more...] about Insmed to defer Phase 3 study of Arikace in US
TOBI Podhaler wins Medical Design Excellence Award
The TOBI Podhaler has been named a bronze winner in the General Hospital Devices and Therapeutics Products division of the Medical Design Excellence Awards presented by UBM Canon and MD+DI. The inhaler, which is marketed by Novartis, was designed by Cambridge Consultants, and Gerresheimer Medical Plastic Systems gets the supply credit. The Sun Pharma Combitide … [Read more...] about TOBI Podhaler wins Medical Design Excellence Award
Mylan and Sunovion settle Brovana patent infringement suit
Mylan has announced that its subsidiary Mylan Specialty (formerly Dey Pharma) has reached an agreement with Sunovion Pharmaceuticals (formerly Sepracor) in which Sunovion "has acknowledged that two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana product." Dey sued Sepracor in 2007 alleging that the latter's Brovana arformoterol tartrate … [Read more...] about Mylan and Sunovion settle Brovana patent infringement suit
Judge rules against Matrixx in Zicam case
"Under the 'ordinary consumer' standard, a product designed for intranasal use is expected not to cause irreparable injury to the nose if used in a foreseeable manner," said U.S. District Judge William Alsup in his decision allowing Californian Michael Nelson's lawsuit against the manufacturer of Zicam nasal gel and spray to go ahead. Nelson sued after losing his … [Read more...] about Judge rules against Matrixx in Zicam case